MyoArete is an innovative biopharmaceutical startup focused on developing cures for Duchenne muscular dystrophy (DMD). The MyoAr pipeline consists of utrophin upregulation-based products for treatments for DMD. Our lead program is MyoAr Small Molecules. These products have been identified using new platform technologies developed at the founder's laboratory at the University of Pennsylvania, with patents pending, and are being exclusively licensed to MyoArete.
Prof. Tejvir S. Khurana is a Professor at the Department of Physiology & Pennsylvania Muscle Institute, Perelman School of Medicine, University of Pennsylvania. Prof. Khurana obtained his MBBS at Delhi University and did his medical training in India, Denmark and Kenya. He obtained his PhD at Harvard University with Prof. Louis M. Kunkel, where he identified and characterized Dystrophin-Related protein or DRP (now renamed utrophin).
The Khurana Lab. has made a number of ground-breaking discoveries in muscle biology including molecular mechanisms of utrophin regulation and development of novel therapeutic strategies for muscle diseases. His laboratory has been funded by foundations including the Dutch Parent Project (Netherlands), Association Francaise contre les Myopathies (France), Muscular Dystrophy Association (USA) as well as federal organizations including the Danish Medical Research Council (SSVF) and the National Institutes of Health (NIH). His honors include membership of the American Society of Clinical Investigation (ASCI) and The Presidential Early Career Award for Scientists and Engineers (PECASE) award from the OSTP, The White House.
Prof. Donna M. Huryn is a Professor at the University of Pittsburgh’s School of Pharmacy and an adjunct Professor at Department of Chemistry at the University of Pennsylvania. She obtained her B.A. at Cornell University and her Ph. D. at the University of Pennsylvania. She began her career as a medicinal chemist in the pharmaceutical industry (Hoffmann-La Roche & Wyeth Research), and contributed to drug discovery efforts for HIV, cancer, asthma, and CNS
disorders with increasing levels of responsibility. In 2004, she returned to academia. Her honors include being elected a Fellow of the American Chemical Society (ACS), recipient of the ACS Philadelphia Local Section Award and Philip S. Portoghese Lectureship, and has held a number of elected positions within the American Chemical Society and the American Association for the Advancement of Science (AAAS). She is Associate Editor of ACS Medicinal Chemistry Letters and co-author of the textbook Medicinal Chemistry (CRC Press). Professor Huryn’s research focuses on the design and synthesis of small molecule probes and drugs to treat cancer, acute kidney injury, neurodegenerative and muscular disorders.
Jeffrey A. James, Ph.D., CLP.
Associate Director, Perelman School of Medicine
Penn Center for Innovation
University of Pennsylvania
3600 Civic Center Boulevard
Philadelphia, PA 19104
For Investment and Partnership Opportunities please contact.